All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @kpwhatspoppin on TikTok · 8s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @kpwhatspoppin's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Tuck the drugs and the drugs are working.
  2. 0:02And the drugs are working.
  3. 0:04I tuck the drugs and the drugs are working.
  4. 0:06Tuck the, Tuck the drugs are working.

@kpwhatspoppin's semaglutide claims, fact-checked

Kp

TikTok creator

2.2M viewsWatch on TikTok

Quick answer

The creator claims semaglutide produced personal weight loss results, a claim consistent with clinical trial data showing average reductions of 15% or more in body weight with weekly 2.4 mg semaglutide. However, the video contains no information about prescriber involvement, titration, side effect monitoring, or whether the product used was FDA-approved or compounded. Viewers cannot assess safety or applicability to their own situation from this content.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @kpwhatspoppin's semaglutide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@kpwhatspoppin's semaglutide claims, fact-checked" from Kp. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator claims semaglutide produced personal weight loss results, a claim consistent with clinical trial data showing average reductions of 15% or more in body weight with weekly 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 bio for discount i was never going to post about my semaglu." In this clip, the useful excerpt is: "Tuck the drugs and the drugs are working." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

FDA has approved semaglutide under the brand name Wegovy specifically for chronic weight management at 2.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator claims semaglutide produced personal weight loss results, a claim consistent with clinical trial data showing average reductions of 15% or more in body weight with weekly 2.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator claims semaglutide produced personal weight loss results, a claim consistent with clinical trial data showing average reductions of 15% or more in body weight with weekly 2.4 mg semaglutide. However, the video contains no information about prescriber involvement, titration, side effect monitoring, or whether the product used was FDA-approved or compounded. Viewers cannot assess safety or applicability to their own situation from this content.
  • STEP 1 trial (Wilding et al., 2021, NEJM): weekly semaglutide 2.4 mg produced average 14.9% body weight loss over 68 weeks in eligible adults.
  • FDA has approved semaglutide under the brand name Wegovy specifically for chronic weight management at 2.4 mg weekly; Ozempic is approved for type 2 diabetes at different doses.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial (Wilding et al., 2021, NEJM): weekly semaglutide 2.4 mg produced average 14.9% body weight loss over 68 weeks in eligible adults.
  • FDA has approved semaglutide under the brand name Wegovy specifically for chronic weight management at 2.4 mg weekly; Ozempic is approved for type 2 diabetes at different doses.
  • FDA issued repeated warnings in 2023 and 2024 that compounded semaglutide products are not equivalent to approved brand-name drugs and have not undergone the same safety review.
  • Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained roughly two-thirds of lost weight within one year of stopping semaglutide, a fact absent from nearly all influencer content.
  • Semaglutide carries a boxed warning: contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
  • FTC endorsement guidelines (revised 2023) require disclosure of material connections including affiliate discount codes, regardless of whether a creator calls the content an ad.
  • A discount code in a TikTok bio is not a substitute for a medical evaluation, prescriber oversight, or individualized dosing guidance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @kpwhatspoppin actually say?

Honestly? Almost nothing verifiable. The transcript is essentially a repeated phrase: "I tuck the drugs and the drugs are working." That's it. There's no dosage mentioned, no timeline, no side effects disclosed, no medical supervision referenced. The caption does more heavy lifting than the video itself, framing this as a personal "semaglutide journey" that "truly worked" for unspecified "weight loss issues."

What the creator actually delivers is vibes and a discount code. The phrase "drugs are working" implies a clear cause-and-effect between semaglutide and weight loss, but no before-and-after data, lab results, or clinical context is offered. The caption's claim that this is "not an ad" sits awkwardly next to a bio link offering a discount, which is a structure that the FTC has increasingly scrutinized as undisclosed sponsorship. Viewers are essentially being asked to trust a six-word loop as a health recommendation.

Does the science back up the general claim that semaglutide works?

On the core premise, yes, the science is real and substantial. Semaglutide does produce meaningful weight loss in clinical populations, and dismissing that would be dishonest.

The landmark STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that weekly subcutaneous semaglutide 2.4 mg produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity or overweight with a weight-related condition. That's not a trivial number. The SELECT trial (Lincoff et al., 2023, NEJM) further showed cardiovascular risk reduction in people with obesity and established cardiovascular disease, which added a meaningful clinical dimension beyond cosmetic weight loss. GLP-1 receptor agonists work primarily by slowing gastric emptying and acting on hypothalamic satiety signals, which reduces caloric intake. The mechanism is legitimate. The benefit is real for eligible patients under medical supervision.

What did they get wrong, or right?

Credit where it's due: semaglutide is not snake oil. If this creator did lose weight on a properly prescribed, medically supervised semaglutide regimen, that experience is plausible and consistent with clinical data. The drug works for many people.

But here's where the video becomes a problem. First, "drugs are working" strips all nuance from a medication that carries a real side effect profile, including nausea, vomiting, pancreatitis risk, and a boxed warning about thyroid C-cell tumors seen in rodent models. Second, presenting a discount-linked recommendation as "not an ad" is a credibility problem, not a minor footnote. Third, the complete absence of any mention of medical oversight normalizes self-directed use of a prescription-only medication. Compounded semaglutide, which is what many discount-code platforms supply, is not equivalent to FDA-approved Wegovy or Ozempic. The FDA has explicitly warned that compounded versions vary in purity, concentration, and formulation. Viewers who follow a discount link have no way of knowing what they're actually ordering.

What should you actually know?

Semaglutide is a prescription medication, full stop. No TikTok video, regardless of view count, changes that. The 2.4 mg weekly dose used in STEP trials is FDA-approved for chronic weight management under the brand name Wegovy, specifically for adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity.

If you're considering GLP-1 therapy, the starting point is a clinician who can review your full medical history, not a bio link. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use semaglutide. Drug interactions, contraindications, and titration schedules matter. The STEP trials also showed that most participants regained significant weight after stopping the drug (Wilding et al., 2022, Diabetes, Obesity and Metabolism), which means this is rarely a short-term intervention. That context is entirely absent from a six-word video loop.

  • Semaglutide produces real, clinically significant weight loss in appropriately selected patients.
  • It is a prescription medication with a real side effect profile and contraindications.
  • Compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic.
  • A discount code in a bio does not constitute medical advice or oversight.
  • Weight often returns after discontinuation, which is critical context for anyone starting treatment.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kp · TikTok creator

2.2M views on this video

Bio for discount! I was never going to post about my semaglutide journey but it is something I never thought would truly work for me with the weight loss issues I have had & wish I would of been aware

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial (wilding et al., 2021, nejm): weekly semaglutide?

STEP 1 trial (Wilding et al., 2021, NEJM): weekly semaglutide 2.4 mg produced average 14.9% body weight loss over 68 weeks in eligible adults.

What does the video say about fda has approved semaglutide under the brand name wegovy specifically?

FDA has approved semaglutide under the brand name Wegovy specifically for chronic weight management at 2.4 mg weekly; Ozempic is approved for type 2 diabetes at different doses.

What does the video say about fda?

FDA issued repeated warnings in 2023 and 2024 that compounded semaglutide products are not equivalent to approved brand-name drugs and have not undergone the same safety review.

What does the video say about wilding et al. (2022, diabetes, obesity?

Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained roughly two-thirds of lost weight within one year of stopping semaglutide, a fact absent from nearly all influencer content.

What does the video say about semaglutide carries a boxed warning: contraindicated in patients with a?

Semaglutide carries a boxed warning: contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

What does the video say about ftc endorsement guidelines (revised 2023) require disclosure of material connections?

FTC endorsement guidelines (revised 2023) require disclosure of material connections including affiliate discount codes, regardless of whether a creator calls the content an ad.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kp, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.